|
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
This framework may help identify novel approaches for promoting chondrocyte homeostasis during aging and obesity.<b>Materials and Methods</b>: Changes in glutathione content and redox ratio were evaluated in three models of chondrocyte stress: (1) age- and tissue-specific changes in joint tissues of 10 and 30-month old F344BN rats, including <i>ex vivo</i> patella culture experiments to evaluate N-acetylcysteine dependent resistance to interleukin-1beta; (2) effect of different durations and patterns of cyclic compressive loading in bovine cartilage on glutathione stress resistance and resilience pathways; (3) time-dependent changes in GSH:GSSG in primary chondrocytes from wild-type and Sirt3 deficient mice challenged with the pro-oxidant menadione.<b>Results</b>: Glutathione was more abundant in cartilage than meniscus or infrapatellar fat pad, although cartilage was also more susceptible to age-related glutathione oxidation.
|
31522568 |
2020 |
|
Obesity
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The studies on mice show that Sirt3 SUMOylation mutation reduces fat mass and antagonizes high-fat diet (HFD)-induced obesity via increasing oxidative phosphorylation and energy expenditure.
|
31302001 |
2019 |
|
Obesity
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Myocardial tissue samples from patients with left ventricular heart failure, with either obesity or normal weight, were processed for the expression of SIRT3 and acetylation profile by Western Blot (WB).
|
31464387 |
2019 |
|
Obesity
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We found that expression of both Sirt6 and Sirt3 was reduced in cardiomyocytes treated with palmitate and in hearts of mice fed with a high-fat, high-sucrose (HF-HS) diet to develop obesity and diabetes.
|
31318577 |
2019 |
|
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
In contrast, RT increased muscle mass without improving SIRT3 in obese male adolescents.
|
29220206 |
2018 |
|
Obesity
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of SIRT3 is a key component of metabolic syndrome, a precondition for obesity, diabetes and cardiovascular diseases.
|
30510203 |
2018 |
|
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim of present study was to test the hypothesis that nicotinamide adenine dinucleotide (NAD<sup>+</sup>)-dependent deacetylase sirtuin-3 (SIRT3) in adipocytes plays a critical role in adipose tissue mitochondrial biology and obesity.
|
29634313 |
2018 |
|
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results suggest that Sirt3 may be a target for amelioration of beta cell dysfunction due to obesity and T2D.Antioxid.Redox Signal.27, 962-976.
|
28375738 |
2017 |
|
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Improving mitochondrial SIRT3 functions by inhibiting SIRT3 acetylation may offer a new therapeutic approach for obesity- and aging-related diseases associated with mitochondrial dysfunction.
|
28808064 |
2017 |
|
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings suggest that SIRT3 positively regulates endothelial insulin sensitivity and show that SIRT3 deficiency and resultant increased mtROS contribute to vascular dysfunction in obesity.
|
27000941 |
2016 |
|
Obesity
|
0.600 |
Biomarker
|
disease |
CTD_human |
Importantly, acetylation of MnSOD, a SIRT3 target, was increased in obese-NGT and obese-GDM vs NW women and was inversely correlated with SIRT3 activity (r = -0.603), suggesting a mechanism for reduced MnSOD activity.
|
23956348 |
2013 |
|
Obesity
|
0.600 |
Biomarker
|
disease |
RGD |
Moreover, hepatic LCAD, a SIRT3 target, was not only reduced 2-fold (p<0.001) but was also hyperacetylated in offspring of obese dams (p<0.005) suggesting decreased hepatic FAO.
|
21901160 |
2011 |
|
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mice lacking SIRT3 (SIRT3KO) placed on a HFD show accelerated obesity, insulin resistance, hyperlipidemia, and steatohepatitis compared to wild-type (WT) mice.
|
21856199 |
2011 |